Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results
May 08, 2017 16:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop
April 27, 2017 09:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors
April 20, 2017 08:05 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
April 18, 2017 07:55 ET
|
Mateon Therapeutics
No Significant CA4P Drug Safety Issues IdentifiedInitial Efficacy in Favor of CA4P, with 22% of CA4P Patients Responding versus 9% in the Control ArmEnrollment in the Study Continuing SOUTH SAN...
Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017
March 31, 2017 09:05 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results
March 30, 2017 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Initial Data from Third Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
March 15, 2017 08:00 ET
|
Mateon Therapeutics
One patient of four (25%) achieved a complete remissionNo dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif., March 15, 2017 (GLOBE...
Mateon Therapeutics to Present at 29th Annual ROTH Conference
March 08, 2017 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors
February 13, 2017 08:00 ET
|
Mateon Therapeutics
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completionThree additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1,...
Mateon Therapeutics to Present at BIO CEO & Investor Conference on February 13, 2017
February 07, 2017 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...